ClinicalTrials.gg

Hepatitis C, Chronic clinical trials

Its pipeline, or its studies — you choose. Free with an account during the beta.

The registry lists 950 studies for Hepatitis C, Chronic across more than 10 countries. 8 are recruiting or about to start. 889 of them are mainly about Hepatitis C, Chronic (how this is decided). Per ClinicalTrials.gov, last updated 2026-11-09.

ClinicalTrials.gov finds 1,510 studies for Hepatitis C, Chronic. How that becomes 950 here

This page counts the studies the registry files under Hepatitis C, Chronic, and those it files under no condition that list Hepatitis C, Chronicthemselves. Each study its search finds is placed by how the registry filed it and by the conditions it lists. ClinicalTrials.gov counts as of Nov 8, 2026. How condition pages count

  1. 1,510Found by its condition searchIt reads the conditions a study lists and their synonyms, and also titles and keywords.
  2. −38List Hepatitis C, Chronic as a condition, but the registry did not file them under itMost often written as “Chronic Hepatitis C Infection” (21), “Chronic Hepatitis C Virus Infection” (4), and “Genotype 1 Chronic Hepatitis C” (3). The registry filed them under other conditions only, most often Hepatitis C (29) and Bronchiolitis Obliterans Syndrome (4).
  3. −522Match it another way312 name it in the title, 5 in a keyword, and 205 by a synonym or other text the search reads.
  4. 950The count on this page43 of them list Hepatitis C, Chronic in their own words; the registry filed them under no condition.

Status

Completed
720
Status unknown
102
Terminated
79
Withdrawn
32
Active, not recruiting
6
Recruiting
5

Phase

Phase 2
244
Phase 3
211
Phase 4
148
Phase 1
115
Early Phase 1
3

Where

United States
256
France
108
Germany
95
Spain
83
Canada
80
Puerto Rico
72

Who develops what

Add Hepatitis C, Chronic to watchlistPro · free during the betaEvery Monday by email · turn it off any time

Every program with a company-led study here in the last two years, whatever its size: 3 programs from 2 companies, 3 with this as their studies’ main aim; 1 with a live phase 3 study; 1 primary completion in the next 12 months.

Comparator & background therapies

What other companies’ phase 2+ studies give as the comparator or the background here (its leading trial sponsor and partners left out): a sign of what new drugs are measured against, not by itself the standard of care, its prescriptions or its market.

DrugLeading trial sponsor · rightsCompanies, last 5 years
RibavirinEarlier onlyPhase 4 trial recorded
Evidence
  • NCT04382937 · PharmaEssentia · Phase 3 · comparator · “PEG-Intron + Ribavirin” · registered Apr 2020
  • NCT03020082 · Ascletis Pharma Inc. · Phase 3 · background · “RBV” · registered Jan 2017
  • NCT02939989 · AbbVie · Phase 3 · background · “Ribavirin” · registered Oct 2016
  • NCT02723084 · AbbVie · Phase 3 · comparator · “ribavirin (RBV)” · registered Mar 2016
  • NCT02716428 · Trek Therapeutics, PBC · Phase 2 · background · “Ribavirin” · registered Mar 2016
Hoffmann-La Roche19% of its industry studies00 studies
peginterferon alfa-2aEarlier only
Evidence
  • NCT03020082 · Ascletis Pharma Inc. · Phase 3 · background · “peginterferon alfa-2a” · registered Jan 2017
  • NCT03020004 · Ascletis Pharma Inc. · Phase 2 · background · “peginterferon alfa-2a” · registered Jan 2017
  • NCT02057887 · Hanmi Pharmaceutical Company Limited · Phase 2 · comparator · “Pegasys” · registered Aug 2013
  • NCT01908335 · Beijing Kawin Technology Share-Holding Co., Ltd. · Phase 2 · comparator · “Pegasys /RBV” · registered Jul 2013
  • NCT01903278 · Beijing Kawin Technology Share-Holding Co., Ltd. · Phase 3 · comparator · “Pegasys /RBV” · registered Jul 2013
Hoffmann-La Roche67% of its industry studiesUS: pharmaand GmbH (FDA 2002)EU: pharmaand GmbH (EMA 2002)00 studies
peginterferon alfa-2bEarlier onlyPhase 4 trial recorded
Evidence
  • NCT04382937 · PharmaEssentia · Phase 3 · comparator · “PEG-Intron + Ribavirin” · registered Apr 2020
  • NCT01871662 · Rottapharm · Phase 3 · background · “Pegylated interferon alfa2b” · registered May 2013
  • NCT01366638 · Johnson & Johnson · Phase 3 · background · “Peginterferon alfa-2b (pegIFN alfa-2b)” · registered Jun 2011
  • NCT00863239 · Biolex Therapeutics, Inc. · Phase 2 · comparator · “PEG-Intron™” · registered Mar 2009
  • NCT00780416 · Tanabe Pharma Corporation · Phase 3 · background · “Peginterferon Alfa-2b” · registered Oct 2008
Merck & Co., Inc80% of its industry studies00 studies

7 more in limited or earlier use — sign in to see them, free.

Programs

“Meets, by arms” reads each study’s arms: vs its arm against the therapy’s; + X vs a combination against it; added to it plus the therapy against the therapy; studied with given together only. The next primary completion is the next phase-3 study’s when there is one.

The 3 programs — sign in to see the whole list, free: filter by phase and aim, sort by late development, direct comparisons or the next primary completion.

Primary completion in the next 12 months (1)

Live phase 2 and 3 studies of these programs. Primary completion is when the main measure’s data collection ends, as the registry states it (most are estimates); results come later, if they are announced.

  • Dec 2026 est.Bemnifosbuvir-Ruzasvir · Atea Pharmaceuticals, Inc. · Phase 3 main aimNCT07037277 C-Forward: Efficacy and Safety of BEM/RZR vs SOF/VEL in Subjects With Chronic HCV — primary endpoint: Portion of subjects achieving HCV RNA less than the lower limit of quantitation (LLOQ) at week 24 · 880 enrolled

Read from ClinicalTrials.gov, industry-led studies. Main aim: this is the study’s judged main condition; named, not the main aim: the sponsor names it, the study is about something else; registry mapping only: only the registry’s mapping put it here. Leading trial sponsor is the company leading the most industry studies of a drug, a measure of trial activity, not of rights. US and EU rights, and Approved: from the regulators’ records (FDA’s Drugs@FDA via openFDA; EMA’s medicines data) — the holder of a marketed or authorized original, generics and other companies’ versions; not rights elsewhere, nor approval for this condition. Phase 4 trial recorded, where neither lists it: a phase 4 study exists somewhere. Not read yet: labels by indication, exclusivity, licenses, line of therapy, academic comparators, sales.

What is being tested here

Drugs under test in Hepatitis C, Chronic studies, those with the most open studies first. Medicines only given beside them are not counted. How drugs are counted

Coming up

1study finishes main data collection within a yearphase 3

Studies recruiting or running, from their records. “Main data collection” ends at the primary completion date, the sponsor’s own estimate, which often moves.

The study

Who these studies take

Of the 5 Hepatitis C, Chronic studies recruiting now, 2 (40%) set no upper age limit and 2 (40%) stop at 75 or younger. 1 (20%) take children under 18. 0 (0%) are for women only and 0 (0%) for men only; 1 (20%) take healthy volunteers.

Recruiting studies that take each age, of 5
AgeWomenMen
101 (20%)1 (20%)
184 (80%)4 (80%)
305 (100%)5 (100%)
405 (100%)5 (100%)
505 (100%)5 (100%)
655 (100%)5 (100%)
754 (80%)4 (80%)
853 (60%)3 (60%)

Across all 950 studies, recruiting or not: 47% stop at 75 or younger and 26% at 65; 6% take children; 1% are for women only and 1% for men only; 8% take healthy volunteers. From each study’s registry entry; the criteria on its page decide.

How long Hepatitis C, Chronic studies take

Of 50 phase 3 interventional studies under Hepatitis C, Chronic, half reached primary completion within 15 months of starting, counting those still running.

Start to primary completionEvery sponsorIndustryNon-industry
Phase 17 mo3–13 · 21 studies——
Phase 217 mo11–30 · 35 studies16 mo10–28 · 28 studies—
Phase 315 mo10–26 · 50 studies14 mo10–26 · 41 studies—
Phase 428 mo18–48 · 24 studies——
Interventional, no phase26 mo14–35 · 24 studies——
Observational32 mo22–54 · 72 studies27 mo18–38 · 34 studies43 mo26–110 · 38 studies

Each figure is the month by which half the studies had reached primary completion, with the range in which the middle half did. Studies still running count until their last registry update; studies that stopped early are left out. Phase 1 includes early phase 1; observational means prospective or not stated, as retrospective and cross-sectional studies date a window of data rather than a study. How these figures are worked out

Studies

Recruiting first, then most recently updated. Showing 50 of 950. Browse all 950 → or search them.